IL13RA2 and glioblastoma: Tri-specific CAR T-cells targeting HER2, IL13Ra2, and EphA2 achieve a wider coverage of antigens, and studies have shown that this strategy prolongs the survival of mice bearing glioblastoma patient-derived xenografts (26).